- Technology Management
- For Industry - Technology Available for Licensing
- Contact Technology Management
- old pages
- title page
- A Modern Approach to Wing Warp for Aircraft Control
- Treatment Of Liver Fibrosis Following Hepatic Injury By Selective Killing Of Activated Liver Stellate Cells
- Compositions and Methods for Treating and Diagnosing Hepatoma
- Vaccine Compositions and Methods That Increase Safety of Anti-Viral Vaccination Without Loss of Efficacy
- Automatic Pressure-Locking Valve Prevents CSF Loss and Herniation During Lumbar Puncture When Intracranial Pressure Is Elevated.
- Immortal Differentiated Type II Lung Epithelial Cell Line (T7)
- Human A Rapid, Reliable Bedside Diagnostic Method For Accurately Determining Feeding Tube Placement In Respiratory Tract, Stomach, Or Small Bowel Of Patients Prior to Enteral Nutrient Administration.
- Human Natural Killer Cell Line - NK 3.3:
- Factor IXa Protease Helix-330 (Region 1)
- In Vitro Method for Concerted Integration of Donor DNA Molecules Into Target DNA Using Retroviral Integrase and a Procedure for Evaluation of Donor DNA Integration.
- SRCAP: A Novel Transcription Protein Having Therapeutic Target and Diagnostic Target Product Development Potential.
- C-Terminal Binding Protein Interacting Protein (CtIP):
- Novel Anti-Coagulation Therapeutics: Agents That Effectively Inhibit Binding of Factor VIIIa (Region 3) With Factor IXa (Region 2) Without Activating Factor X.
- Genetically Modified Activated Protein C with Reduced Anticoagulant Properties
- C22: A Conditionally Immortalized Mouse Clara Cell Line
Treatment Of Liver Fibrosis Following Hepatic Injury By Selective Killing Of Activated Liver Stellate Cells
Inventor: Ranjit Ray, Ratna Ray, Arnab Basu and Yie-Hwa Chang
Liver fibrosis is a central feature of the majority of chronic liver injuries caused by metabolic, genetic, viral, and cholestatic diseases in humans. Fibrosis distorts the liver architecture (cirrhosis) and is associated with a marked disturbance of liver function that results in significant morbidity and mortality. Hepatic stellate cells (HSC), which compose about 15% of the total number of resident liver cells, are the main hepatic cell type involved in the development of liver fibrosis following injury.
Compositions and methods are described for selectively inhibiting the proliferation of stellate cells responsible for the development of fibrosis in the liver following injury. A novel protein present in conditioned media from immortalized hepatocytes appears to induce apoptosis and selectively kill liver stellate cells.
Application: Treatment of liver fibrosis
Keywords: Stellate cells, liver fibrosis, cirrhosis, apoptosis
Patent: U.S. Patent Application 10/888,962 (Filed: July 9, 2004)
Reference Number: SLU-1026